A multicentre, retrospective study to evaluate the safety, efficacy, and tolerability of Simeprevir and Sofosbuvir with or without Ribavirin in patients with hepatitis C genotype-1 infection after an orthotopic liver transplantation

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Simeprevir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use

Most Recent Events

02 Mar 2016 New trial record
25 Feb 2016 Results published in the Liver Transplantation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight